 |
|
FMR1 Premutations Associated With Fragile X–Associated Tremor/Ataxia Syndrome in Multiple System Atrophy
Valérie Biancalana, PhD;
Mathias Toft, MD;
Isabelle Le Ber, MD;
François Tison, MD;
Elisabeth Scherrer;
Stephen Thibodeau, PhD;
Jean Louis Mandel, MD, PhD;
Alexis Brice, MD;
Matthew J. Farrer, PhD;
Alexandra Dürr, MD, PhD
Arch Neurol. 2005;62:962-966.
Background Fragile X–associated tremor/ataxia syndrome (FXTAS), a novel disorder in male carriers of premutations of the fragile X mental retardation 1 gene (FMR1), was recently described. The clinical presentation of FXTAS most closely resembles multiple system atrophy (MSA) because both disorders manifest with cerebellar ataxia, intention tremor, autonomic dysfunction, and parkinsonism. It has been proposed that FXTAS might be a common neurodegenerative disorder.
Objective To determine whether FXTAS accounts for patients currently diagnosed as having MSA or a related clinical diagnosis.
Design Patients with MSA or related phenotypes were examined by experienced movement disorders neurologists, and DNA samples were obtained for genetic study.
Setting Salpêtrière Hospital.
Patients Seventy-seven patients clinically diagnosed as having MSA, 19 as having olivopontocerebellar atrophy, and 27 as having cerebellar ataxia.
Main Outcome Measure The number of FMR1 repeats was determined in all patients by polymerase chain reaction. Alleles above 40 CGG repeats were controlled by Southern blot analysis.
Results Two patients carried FMR1 premutations of 110 and 135 repeats: a man with a familial form of cerebellar ataxia and a woman diagnosed as having MSA–cerebellar type. In addition, 9 patients (7%) carried alleles in the intermediate size range, from 41 to 53 repeats.
Conclusions We confirm the recent initial description of FXTAS in women. Our data suggest that FXTAS is rare in MSA and indicate that FXTAS might be less prevalent than proposed.
Author Affiliations: Institut de Génétique et de Biologie Moléculaire et Cellulaire, Strasburg, France (Drs Biancalana and Mandel and Ms Scherrer); Department of Neuroscience, Mayo Clinic, Jacksonville, Fla (Drs Toft and Farrer); INSERM U679 and Département de Génétique, Cytogénétique et Embryologie, Hôpital de la Salpêtrière, Paris, France (Drs Le Ber, Brice, and Dürr); Service de Neurologie, Centre Hospitals-Universitaire, Bordeaux, France (Dr Tison); and Mayo Clinic, Rochester, Minn (Dr Thibodeau).
|
